Back to results
US 9,447,026 B2Granted
Bicyclic analgesic compounds
AssigneeKalyra Pharmaceuticals, Inc.
InventorKevin Duane Bunker
Life of this patent
Estimating the term…
Abstract
Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound described herein.
Claims74
A method for reducing pain or fever comprising administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein Formula (I) has the structure:
- wherein
- R1 is H, —CH3, or a substituted or unsubstituted (C2 to C5) alkyl;
- R2 is H or —C(═Y)R4;
- R3 is H, F, D, hydroxy, NH2, a (C1 to C10) alkoxy, a substituted or unsubstituted (C1 to C30) alkyl, a substituted or unsubstituted (C2 to C30) alkenyl, a substituted or unsubstituted (C2 to C30) alkynyl, a substituted or unsubstituted (C3 to C30) cycloalkyl, a substituted or unsubstituted (C3 to C30) cycloalkenyl, a substituted or unsubstituted (C8 to C30) cycloalkynyl, a substituted or unsubstituted —N-linked amido, —(C═O)L or —O(C═O)R5, wherein—(C═O)L is a hydrolyzable prodrug ester leaving group,
- R4 is a substituted or unsubstituted (C1 to Cm) alkyl;
- R5 is a substituted or unsubstituted (C1 to C6) alkyl, a substituted or unsubstituted aryl(C1-6 alkyl) or
- and
- Y is S or O.
5 more elements
A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
- wherein
- R1 is H, —CH3, —CF3, or a substituted or unsubstituted (C2 to C5) alkyl;
- R2 is —C(═Y)R4;
- and
- R3 is H, F, D, hydroxy, NH2, a (C1 to C10) alkoxy, a substituted or unsubstituted (C1 to C30) alkyl, a substituted or unsubstituted (C2 to C30) alkenyl, a substituted or unsubstituted (C2 to C30) alkynyl, a substituted or unsubstituted (C3 to C30) cycloalkyl, a substituted or unsubstituted (C3 to C30) cycloalkenyl, a substituted or unsubstituted (C8 to C30) cycloalkynyl, a substituted or unsubstituted —N-linked amido, —(C═O)L or —O(C═O)R5, wherein —(C═O)L is a hydrolyzable prodrug ester leaving group;
- or
- R1 is H, —CH3, —CF3, or a substituted or unsubstituted (C2 to C5) alkyl;
- R2 is H;
- R3 is H, D, a (C1 to C10) alkoxy, a substituted (C1 to C30) alkyl, an unsubstituted (C2 to C30) alkyl, a substituted or unsubstituted (C2 to C30) alkenyl, a substituted or unsubstituted (C2 to C30) alkynyl, a substituted or unsubstituted (C3 to C30) cycloalkyl, a substituted or unsubstituted (C3 to C30) cycloalkenyl, a substituted or unsubstituted (C8 to C30) cycloalkynyl, a substituted or unsubstituted —N-linked amido or —O(C═O)R5;
- R4 is a substituted or unsubstituted (C1 to C10) alkyl;
- R5 is a substituted or unsubstituted (C1 to C6) alkyl, a substituted or unsubstituted aryl(C1-6 alkyl) or
- and
- Y is S or O;
- and
- with the proviso that when R3 hydrogen, then R1 and R2 cannot both be hydrogen.
12 more elements
Dependencies are inferred from the claim text.